Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISEE2009 open-label extension of avacincaptad pegol for geographic atrophy after GATHER2
MOH_2023-02-07_012326Phase 3Active, not recruiting
- Sponsor
- Astellas Pharma
- Start
- Jan 2023
- Modality
- Vaccine mRNA → mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of avacincaptad pegol in geographic atrophy (GA) and age-related macular degeneration (AMD), sponsored by Astellas Pharma. Started Jan 2023; status: active, not recruiting.
02
Drugs
avacincaptad pegol
03
Conditions
geographic atrophy (GA)age-related macular degeneration (AMD)
Beyond the preview
Go deeper on MOH_2023-02-07_012326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-02-07_012326.